Huons Co., Ltd.
Clinical trials sponsored by Huons Co., Ltd., explained in plain language.
South Korean pharmaceutical company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a single pill tackle both blood pressure and cholesterol? Results expected Feb 2027 (estimated)
- Can a cholesterol drug and a blood pressure drug be safely combined? Results expected Apr 2027 (estimated)
- New eye drop hopes to soothe dry eye sufferers Results expected Jun 2027 (estimated)
-
New eye drop aims to lower pressure in glaucoma patients
Disease control Recruiting nowThis Phase 3 trial tests a new eye drop called HUC3-637 in 206 adults with primary open-angle glaucoma or ocular hypertension. The goal is to see if it safely lowers eye pressure better than an existing active control. Participants will use the drops daily and have their eye pres…
Phase 3 • Sponsor: Huons Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New eye drop hopes to soothe dry eye sufferers
Symptom relief Recruiting nowThis study tests a new eye drop called HUC1-394 in 150 adults with moderate to severe dry eye disease. Participants will use the drops or a placebo for a period to see if the drug reduces eye surface damage and improves symptoms. The goal is to find the best dose and frequency.
Phase 2 • Sponsor: Huons Co., Ltd. • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC